Health Condition 1: H201- Chronic iridocyclitis
Conditions
Interventions
Intervention1: TOFACITINIB: dose 5mg oral tablet twice a day for atleast 3 months
Control Intervention1: NIL: NIL
Sponsors
AIIMS DELHI
Eligibility
Inclusion criteria
Inclusion criteria: All phenotypes of non-infectious pediatric anterior uveitis (with or without intermediate spillover) cases can be included provided- -Patients unable to afford adalimumab. -Inability to maintain remission on combination of prednisolone less than 2 drops per day along with methotrexate for at least 3 months -Patients off adalimumab for at least 3 months
Exclusion criteria
Exclusion criteria: -Any infectious uveitis like cases of viral anterior uveitis or tuberculosis. -Systemic contraindication to tofacitinib. -Positive for Hepatitis C and Hepatitis B. -Concomitant type 1 Diabetes Mellitus, active tuberculosis. -Inability to take prophylactic Isoniazid if Mantoux or Interferon Gamma Release Assay positive. -Hemoglobin less than 9g/dl, Absolute Neutrophil Count less than 1000 cells/mm cube or Absolute Leucocyte Count less than 500 cells/mm cube.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Anterior Chamber cells by more than or equal to 2 grades at 12 weeksTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in the Anterior Chamber cells by 1 gradeTimepoint: 12 weeks;Best corrected visual acuity Timepoint: 12 weeks;Central macular thicknessTimepoint: 12 weeks;Ability to taper topical steroidsTimepoint: 12 weeks;Mean duration of treatment for remission of diseaseTimepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactROHAN CHAWLA
Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of India Sciences, New Delhi
Outcome results
None listed